Nifurtimox for Treatment of Chagas Disease in Pediatric Patients: the Challenges of Applying Pharmacokinetic-Pharmacodynamic Principles to Dose Finding

被引:0
作者
Heino Stass
Ibrahim Ince
Ulrike Grossmann
Boris Weimann
Stefan Willmann
机构
[1] Bayer AG,Research & Development, Pharmaceuticals
[2] Clinical PK CV,Clinical Development & Operations
[3] Research & Development,undefined
[4] Pharmaceuticals,undefined
[5] Bayer AG,undefined
[6] Bayer AG,undefined
[7] Chrestos Concept GmbH & Co. KG,undefined
来源
The AAPS Journal | / 24卷
关键词
efficacy; exposure; nifurtimox; pediatric; safety;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 70 条
[1]  
Bern C(2015)Chagas’ disease N Engl J Med 373 1882-164
[2]  
Álvarez-Hernández D-A(2018)Chagas disease: current perspectives on a forgotten disease Rev Med Hosp Gen Méx 81 154-27
[3]  
Franyuti-Kelly G-A(1969)Acute period of Chagas’ disease and its treatment with Bay 2502 Bol Chil Parasitol 24 24-364
[4]  
Díaz-López-Silva R(1976)Clinico-therapeutic trial with benzonidazole in Chagas’ disease Rev Inst Med Trop Sao Paulo 18 357-1635
[5]  
González-Chávez A-M(2021)Serological response to nifurtimox in adult patients with chronic Chagas disease: an observational comparative study in Argentina PLoS Negl Trop Dis. 15 e0009801-e-555
[6]  
González-Hermosillo-Cornejo D(1972)The effect of nifurtimox in acute Chagas’ infection Arzneimittelforschung 22 1624-555
[7]  
Vázquez-López R(2022)Population pharmacokinetics of nifurtimox in adult and pediatric patients with Chagas’ disease J Clin Pharmacol 15 542-243
[8]  
Bocca Tourres CL(2021)Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO) PLoS Negl Trop Dis 10 542-553
[9]  
Ferreira HD(2021)Biopharmaceutical characteristics of nifurtimox tablets for age- and body weight-adjusted dosing in patients with Chagas disease Clin Pharmacol Drug Dev 10 106050-undefined
[10]  
Vizcaya D(2021)Biopharmaceutical characteristics of nifurtimox tablets – implications for quality assurance and clinical use Eur J Pharm Sci 222 237-undefined